Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Common Equity (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Common Equity for 4 consecutive years, with $43.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Common Equity fell 5.37% to $43.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $43.7 million, a 5.37% decrease, with the full-year FY2024 number at $33.0 million, down 51.56% from a year prior.
  • Common Equity was $43.7 million for Q3 2025 at Orchestra BioMed Holdings, up from $295000.0 in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $99.8 million in Q1 2023 to a low of $78000.0 in Q1 2022.
  • A 4-year average of $50.8 million and a median of $52.5 million in 2022 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: soared 127787.18% in 2023, then crashed 99.33% in 2025.
  • Orchestra BioMed Holdings' Common Equity stood at $52.5 million in 2022, then rose by 29.52% to $68.0 million in 2023, then tumbled by 51.56% to $33.0 million in 2024, then soared by 32.71% to $43.7 million in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Common Equity are $43.7 million (Q3 2025), $295000.0 (Q2 2025), and $16.9 million (Q1 2025).